Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis–hepatocellular carcinoma
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-09 · 399 (12) · 19597-19616
DOI: 10.1007/s00210-026-05573-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 26.06.2026. Verfasst von Ameera Al Mansoori und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, UAE. Hauptthemen laut MEDLINE: Sorafenib, Cyclohexenes, Carcinoma, Hepatocellular, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Sorafenib (SB) remains an option for advanced HCC in patients who cannot receive, or do not respond to, immunotherapy. Safranal (SF), a bioactive saffron compound, possesses anti-inflammatory and anticancer properties. This study evaluated SF with SB in a diethylnitrosamine-induced cirrhosis-HCC rat model. Rats were assigned to control, HCC, HCC + SB, HCC + SF, and HCC + SF + SB groups and treated for three weeks. Liver morphology, function, histology, apoptosis, cell proliferation, transcriptomics, and metabolomics analyses were assessed. Combination therapy inhibited hepatic nodules and restored liver architecture. Biochemical and histopathological analyses confirmed improved liver function, reduced fibrosis, vacuolation, and decreased α-SMA expression. Combined treatment improved apoptosis, antiproliferative effects and caused G2/M cell cycle arrest. Inflammatory markers (TNF-α, NF-κB, COX-2, MMP9, and β-catenin) were downregulated. Multiomics confirmed modulation of apoptosis, inflammation, oxidative stress, and metabolic pathways. SF potentiates a promising anti-HCC therapeutic efficacy of SB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, UAE.
- Department of Biology, United Arab Emirates University, Al Ain, UAE.
- PureLab, Abu Dhabi, UAE.
- Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.
- Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, UAE.
- Biology Department, National Organization for Drug Control and Research, Giza, 12611, Egypt.
Zitieren
APA
Al Mansoori, A., Baig, B., Harati, R., Alhamidi, R. S., Hamza, A. A., Al-Salam, S., Le, A., Zhang, C., Khare, P., Hamoudi, R., & Amin, A. (2026). Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis–hepatocellular carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(12), 19597-19616. https://doi.org/10.1007/s00210-026-05573-6
Vancouver
Al Mansoori A, Baig B, Harati R, Alhamidi RS, Hamza AA, Al-Salam S, et al. Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis–hepatocellular carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(12):19597-19616. doi:10.1007/s00210-026-05573-6
BibTeX
@article{AlMansoori2026,
author = {Al Mansoori, Ameera and Baig, Badriya and Harati, Rania and Alhamidi, Reem Sami and Hamza, Alaaeldin A and Al-Salam, Suhail and Le, Anne and Zhang, Cissy and Khare, Pratik and Hamoudi, Rifat and Amin, Amr},
title = {Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis–hepatocellular carcinoma},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {12},
pages = {19597--19616},
doi = {10.1007/s00210-026-05573-6}
}
EUVIMED